GABARAPL2 and gastric cancer: Studies have found that GABARAPL2 may be a gene related to mitophagy, and its expression was further validated through RT-qPCR and IHC, indicating that GABARAPL2 may be a prognostic biomarker and a candidate therapeutic target for GC (59).